Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study ("BACKBEAT study"), resulting in an estimated more than 24-fold increase in the potentially eligible